Shares of Anthem BioSciences rose after Citi initiated coverage with a Buy rating and a target price of ₹870, implying over 20% upside. Ana...

Jefferies has initiated coverage on Sai Life Sciences with a 'Buy' rating and a Rs 1,300 target price, citing its integrated 'follow-the-mo...

Indian drugmakers anticipate a mixed third quarter. Domestic sales and new specialty drugs will drive growth. US generics will see new prod...

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...

Avendus Future Leaders Fund and SBI Life Insurance have collectively invested ₹300 crore in Aragen Life Sciences, acquiring a 2.5% stake in...

Anthem Biosciences share price: Anthem’s IPO did not include a fresh issue, with all proceeds going to existing shareholders. Prior to the ...

Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit h...

Anthem Biosciences' Rs 3,395 crore IPO will open on July 14 as a complete Offer for Sale by promoters and investors. The Bengaluru-based CR...

Global asset manager TPG plans to offload 12.5 million shares (6% stake) in Sai Life Sciences for $102 million. The deal comes at a 2.5% di...

India's contract drug makers are seeking government support to remove regulatory hurdles and speed up raw material import clearances. With ...

India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing pressures, and demand...

India's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...

We are constructive on markets and believe the recent correction offers a good entry point to start accumulation for long term wealth gener...

Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True Nort...

Anthem Biosciences has filed its DRHP for an IPO. The issue comprises an offer for sale of up to Rs 3,395 crore by promoters and investors....

The issue gives a partial exit to private equity investors TPG Asia and HBM. The promoter share will be diluted from 41.8% to 35.2%. The is...

India could take 8-10% of the global outsourcing share for Contract Research Development and Manufacturing Organisations by 2033 due to wor...